Costochondritis Market Research Report – Forecast to 2027

Costochondritis Market Research Report, by Diagnosis (Cardiac MRI Tests, CT scan), Treatment (Medications and Surgery), End-User (Hospitals and Clinics, Ambulatory Surgical Centers, Diagnostic Centers, Research Centers) – Forecast Till 2027

ID: MRFR/Pharma/5038-HCR | | Region: Global | 90 pages

Costochondritis Market Scenario:


Costochondritis is an inflammatory condition of the cartilage which connects a rib to the sternum. It is sometimes called chest wall pain, costosternal chondrodynia, or costosternal syndrome. The pain caused by costochondritis might be similar to that of a heart attack. Costochondritis is a common cause of chest pain in adolescents and children. It is estimated that the costochondritis market is expected to register an increasing CAGR during the forecast period from 2018 to 2023.


The factors causing costochondritis can be injury in chest, physical strain, osteoarthritis, arthritis, ankylosing spondylitis, and tumors (cancerous or noncancerous).  Also, costochondritis may be caused by bacterial, viral, and fungal infections. According to the Centers for Disease Control and Prevention, August 2018, it has been estimated that 22.7% of the US adults had some form of rheumatoid arthritis from 2013 to 2015. The growing percentage of arthritis patients would support the costochondritis market positively.


However, factors such as the high cost of surgical procedures, expensive treatments, and side effects related to treatments are expected to restrict the market growth during the forecast period.


Segmentation


The global costochondritis market is segmented on the basis of diagnosis, treatment, and end-user. The costochondritis market, by diagnosis, is categorized into various tests. The test is sub-segmented into echocardiogram, electrocardiogram, stress tests, cardiac catheterization, chest X-ray, cardiac MRI, and CT scan. On the basis of treatment, the market is segmented into medications, therapy, and surgery.


The medications treatment is further sub-segmented into nonsteroidal anti-inflammatory drugs, narcotics, antidepressants, and anti-seizure drugs. Therapy is sub-segmented into stretching exercises and nerve stimulation. On the basis of end-user, the market is segmented into hospitals and clinics, ambulatory surgical centers, diagnostic centers, research centers, and others.


On the basis of region, the global costochondritis market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the UAE, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.


Key Players



  • KemPharm

  • GlaxoSmithKline plc

  • Biovail Corporation

  • Aurobindo Pharma

  • Pfizer Inc

  • Recro Pharma Inc

  • LUPIN

  • Bausch Health Companies Inc

  • Avenue Therapeutics


Regional Market Summary


Global Costochondritis Market Share (%), by Region, 2017


Costochondritis Market Share


Sources: National Cancer Institute, Cancer Research UK, the American Cancer Society, Inc, US Department of Health and Human Services National Institutes of Health


It is estimated that North America dominated the global costochondritis market owing to the increased cardiac diseases, increasing prevalence of syphilis, innovations in clinical practice, heart research, and access to heart treatments in this region. According to the Centers for Disease Control and Prevention (CDC), September 2017, the total syphilis cases reported to CDC increased by 17.8% during 2015 to 2016. The increase in the cases of syphilis supports the market growth in this region.


Europe stood the second largest in the costochondritis market owing to increasing hypertension and heart attack cases. According to the Public Health England in January 2017,


High blood pressure is the third highest risk factor for disease in the UK. It affected one in four adults and around 12.5 million people in 2015 in England. This number is expected to increase during the forecast period.  Such a high incidence of high blood pressure supports the growth of costochondritis in this region.


Asia-Pacific was estimated to be the fastest-growing region for the global costochondritis market in 2017. The market is expected to witness growth owing to the rising prevalence of heart problems, car accidents, and changing lifestyles.


The Middle East and Africa holds the least share in the global costochondritis market due to the presence of low health expenditure, low awareness of innovative technology, and economically diverse countries. However, the market is expected to witness growth due to increasing cardiac care programs and an increase in investments in research and development in the Middle East.


Global Costochondritis Market, by Diagnosis



  • Tests

  • Echocardiogram

  • Electrocardiogram

  • Cardiac catheterization

  • Chest X-ray

  • Cardiac MRI

  • CT scan


Global Costochondritis Market, by Treatment



  • Medications

  • Nonsteroidal anti-inflammatory drugs

  • Narcotics

  • Antidepressants

  • Anti-seizure drugs

  • Therapy

  • Stretching exercises

  • Nerve stimulation

  • Surgery


Global Costochondritis Market, by End-Users



  • Hospitals and clinics

  • Ambulatory surgical centers

  • Diagnostic centers

  • Research centers

  • Others


Global Costochondritis Market, by Region



  • Americas

  • Europe

  • Asia-Pacific

  • Middle East & Africa


Intended Audience



  • Pharmaceutical companies

  • Biotechnological institutes

  • Government and private laboratories

  • Research and Development (R&D) companies

  • Medical research laboratories

  • Market research and consulting service providers


 



Report Scope:
Report Attribute/Metric Details
  Market Size   Significant Value
  CAGR   2019-2027: Substantial CAGR
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Diagnosis, Treatment, And End-User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   KemPharm, GlaxoSmithKline plc, Biovail Corporation, Aurobindo Pharma, Pfizer Inc., Recro Pharma Inc., LUPIN, Bausch Health Companies Inc., Avenue Therapeutics, and others
  Key Market Opportunities   Innovative technology, and economically diverse countries
  Key Market Drivers   High incidence of high blood pressure


Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :


The factors triggering costochondritis market would be physical strain, injury in chest, ankylosing spondylitis, osteoarthritis, arthritis, and tumors (cancerous or noncancerous).

Factors like high surgery costs, expensive treatments, and side-effects would take the costochondritis market.

The treatments included in costochondritis market are therapy, medications, and surgery.

Various tests in the costochondritis market are chest X-ray, cardiac MRI, electrocardiogram, echocardiogram, cardiac catheterization, stress tests, and CT scan.

North America would dominate the global cotiochondritis market.

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Costochondritis Market, by Diagnosis

6.1 Introduction

6.2 Tests

6.2.1 Echocardiogram

6.2.2 Electrocardiogram

6.2.3 Cardiac catheterization

6.2.4 Chest X-ray

6.2.5 Cardiac MRI

6.2.6 CT scan

Chapter 7. Global Costochondritis Market, by Treatment

7.1 Introduction

7.2 Medications

7.2.1 Nonsteroidal anti-inflammatory drugs

7.2.2 Narcotics

7.2.3 Antidepressants

7.2.4 Anti-seizure drugs

7.3 Therapy

7.3.1 Stretching exercises

7.3.2 Nerve stimulation

7.4 Surgery

Chapter 8. Global Costochondritis Market, by End-Users

8.1 Introduction

8.2 Hospitals and clinics

8.3 Ambulatory Surgical Centers

8.4 Diagnostic Centers

8.5 Research centers

8.6 Others

Chapter 9. Global Costochondritis Market, by Region

9.1 Introduction

9.2 America

9.2.1 North America

9.2.1.1 US

9.2.1.2 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 UK

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia-Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia-Pacific

9.5 Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of the Middle East & Africa


Chapter 10. Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

Chapter 11 Company Profiles

11.1 KemPharm

11.1.1 Company Overview

11.1.2 Type Overview

11.1.3 Financials

11.2.4 Key Developments

11.1.5 SWOT Analysis

11.2 GlaxoSmithKline plc

11.2.1 Company Overview

11.2.2 Type Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Biovail Corporation

11.3.1 Company Overview

11.3.2 Type Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Aurobindo Pharma

11.4.1 Company Overview

11.4.2 Type/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Pfizer Inc.

11.5.1 Company Overview

11.5.2 Type Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.5.5 SWOT Analysis

11.6 Recro Pharma Inc.

11.6.1 Company Overview

11.6.2 Type Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.6.5 SWOT Analysis

11.7 LUPIN

11.7.1 Overview

11.7.2 Type Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 BAUSCH HEALTH COMPANIES INC.

11.8.1 Overview

11.8.2 Type Overview

11.8.3 Financials

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.9 Avenue Therapeutics

11.9.1 Overview

11.9.2 Type Overview

11.9.3 Financials

11.9.4 Key Developments

11.9.5 SWOT Analysis

11.10 Others

Chapter 12 Appendix


LIST OF TABLES

Table 1 Global Costochondritis Market Industry Synopsis, 2020–2027

Table 2 Global Costochondritis Market Estimates & Forecast, 2020–2027, (USD Million)

Table 3 Global Costochondritis Market, by Region, 2020–2027, (USD Million)

Table 4 Global Costochondritis Market, by Diagnosis, 2020–2027, (USD Million)

Table 5 Global Costochondritis Market, by Treatment, 2020–2027, (USD Million)

Table 6 Global Costochondritis Market, by End-User, 2020–2027, (USD Million)

Table 7 North America: Global Costochondritis Market, by Diagnosis, 2020–2027, (USD Million)

Table 8 North America: Global Costochondritis Market, by Treatment, 2020–2027, (USD Million)

Table 9 North America: Global Costochondritis Market, by End-User, 2020–2027, (USD Million)

Table 10 US: Global Costochondritis Market, by Diagnosis, 2020–2027, (USD Million)

Table 11 US: Global Costochondritis Market, by Treatment, 2020–2027, (USD Million)

Table 12 US: Global Costochondritis Market, by End-User, 2020–2027, (USD Million)

Table 13 Canada: Global Costochondritis Market, by Diagnosis, 2020–2027, (USD Million)

Table 14 Canada: Global Costochondritis Market, by Treatment, 2020–2027, (USD Million)

Table 15 Canada: Global Costochondritis Market, by End-User, 2020–2027, (USD Million)

Table 16 South America: Global Costochondritis Market, by Diagnosis, 2020–2027, (USD Million)

Table 17 South America: Global Costochondritis Market, by Treatment, 2020–2027, (USD Million)

Table 18 South America: Global Costochondritis Market, by End-User, 2020–2027, (USD Million)

Table 19 Europe: Global Costochondritis Market, Diagnosis, 2020–2027, (USD Million)

Table 20 Europe: Global Costochondritis Market, by Treatment, 2020–2027, (USD Million)

Table 21 Europe: Global Costochondritis Market, by End-User, 2020–2027, (USD Million)

Table 22 Western Europe: Global Costochondritis Market, by Diagnosis, 2020–2027, (USD Million)

Table 23 Western Europe: Global Costochondritis Market, by Treatment, 2020–2027, (USD Million)

Table 24 Western Europe: Global Costochondritis Market, by End-User, 2020–2027, (USD Million)

Table 25 Eastern Europe: Global Costochondritis Market, by Diagnosis, 2020–2027, (USD Million)

Table 26 Eastern Europe: Global Costochondritis Market, by Treatment, 2020–2027, (USD Million)

Table 27 Eastern Europe: Global Costochondritis Market, by End-User, 2020–2027, (USD Million)

Table 28 Asia-Pacific: Global Costochondritis Market, by Diagnosis, 2020–2027, (USD Million)

Table 29 Asia-Pacific: Global Costochondritis Market, by Treatment, 2020–2027, (USD Million)

Table 30 Asia-Pacific: Global Costochondritis Market, by End-User, 2020–2027, (USD Million)

Table 31 Middle East & Africa: Global Costochondritis Market, by Diagnosis, 2020–2027, (USD Million)

Table 32 Middle East & Africa: Global Costochondritis Market, by Treatment, 2020–2027, (USD Million)

Table 33 Middle East & Africa: Global Costochondritis Market, by End-User, 2020–2027, (USD Million)


LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for the Global Costochondritis Market

Figure 3 Market Dynamics for the Global Costochondritis Market

Figure 4 Global Costochondritis Market Share, by diagnosis 2020

Figure 6 Global Costochondritis Market Share, by treatment, 2020

Figure 6 Global Costochondritis Market Share, by End-User, 2020

Figure 7 Global Costochondritis Market Share, by Region, 2020

Figure 8 North America Costochondritis Market Share, by Country, 2020

Figure 9 Europe Prescribed Health Apps Share, by Country, 2020

Figure 10 Asia-Pacific Costochondritis Market Share, by Country, 2020

Figure 11 Middle East & Africa Costochondritis Market Share, by Country, 2020

Figure 12 Global Costochondritis Market: Company Share Analysis, 2020 (%)

Figure 13 KemPharm: Key Financials

Figure 14 KemPharm: Segmental Revenue

Figure 15 KemPharm: Geographical Revenue

Figure 16 GlaxoSmithKline plc: Key Financials

Figure 17 GlaxoSmithKline plc: Segmental Revenue

Figure 18 GlaxoSmithKline plc: Geographical Revenue

Figure 19 Biovail Corporation: Key Financials

Figure 20 Biovail Corporation: Segmental Revenue

Figure 21 Biovail Corporation: Geographical Revenue

Figure 22 Aurobindo Pharma: Key Financials

Figure 23 Aurobindo Pharma: Segmental Revenue

Figure 24 Aurobindo Pharma: Geographical Revenue

Figure 25 Pfizer Inc.: Key Financials

Figure 26 Pfizer Inc.: Segmental Revenue

Figure 27 Pfizer Inc.: Geographical Revenue

Figure 28 Recro Pharma Inc.: Key Financials

Figure 29 Recro Pharma Inc.: Segmental Revenue

Figure 30 Recro Pharma Inc.: Geographical Revenue

Figure 31 LUPIN: Key Financials

Figure 32 LUPIN: Segmental Revenue

Figure 33 LUPIN: Geographical Revenue

Figure 34 Bausch Health Companies Inc.: Key Financials

Figure 35 Bausch Health Companies Inc.: Segmental Revenue

Figure 36 Bausch Health Companies Inc.: Geographical Revenue

Figure 37 Avenue Therapeutics: Key Financials

Figure 38 Avenue Therapeutics: Segmental Revenue

Figure 39 Avenue Therapeutics: Geographical Revenue